Abstract
Eribulin mesylate was approved in the US in 2010 for metastatic breast cancer (mBC) following at least two chemotherapeutic regimens; prior therapy should include anthracycline and taxane in the adjuvant or metastatic setting. With the changing treatment landscape in HR+/HER2- mBC, the main objective of our analyses was to assess the real-world clinical effectiveness of eribulin in HR+/HER2- mBC, when prescribed consistent with the US label.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
